The relationship of PON1 QR 192 and LM 55 polymorphisms with serum paraoxonase activities of Turkish diabetic patients

Toxicology and Industrial Health

Volumn 27, Issue 10, 2011, Pages 873-878

  Altuner, Durdu ^a   Ates, Ilker ^a   Suzen, Sinan H ^a   Koc, Gonul Varan ^b   Aral, Yalcin ^b   Karakaya, Asuman ^a  

^a ANKARA UNIVERSITY   (Turkey)

^b ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

diabetes; lipid peroxidation; PON1 LM55 polymorphism; PON1 QR192 polymorphism; Serum PON1 activities

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; ENZYME ACTIVITY; FEMALE; GENETIC VARIABILITY; GENOTYPE; HUMAN; LIPID PEROXIDATION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK FACTOR; TURKEY (REPUBLIC); XENOBIOTIC STRESS;

ADULT; ARYLDIALKYLPHOSPHATASE; DIABETES MELLITUS, TYPE 2; FEMALE; GENOTYPE; HUMANS; LIPID PEROXIDATION; LIPIDS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 81255143128     PISSN: 07482337     EISSN: 14770393     Source Type: Journal    
DOI: 10.1177/0748233711399317     Document Type: Article

References (28)

1. Abbott CA, Mackness MI, Kumar S, Boulton AJ, Durrington PN. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arteriosclerosis Thrombosis and Vascular Biology. 1995 ; 15: 1812-1818
2. Adkins S, Gan KN, Mody M, La Du BN. Molecular basis for the polymorphic forms of human serum paraoxonase/Arylesterase: glutamine or arginine at position 191, for the respective A or B allosymes. The American Journal of Human Genetics. 1993 ; 52: 598-608 (Pubitemid 23311330)
3. Agachan B, Yilmaz H, Karaali Z, İsbir T. Paraoxonase 55 and 192 polymorphism and its relationship to serum paraoxonase activity and serum lipids in Turkish patients with non-insulin dependent diabetes mellitus. Cell Biochemistry and Function. 2004 ; 22: 163-168 (Pubitemid 38649473)
4. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, LA Du BN. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. Journal of Clinical Investigation. 1998 ; 101: 1581-1590 (Pubitemid 28198486)
5. Billecke S, Draganov D, Counsell R, Stetson P, Watson C, Hsu C, La Du BN. Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metabolism and Disposition. 2000 ; 28: 1335-1342
6. Blatter-Garin MC, James RW, Dussoix P, Blanche H, Ruiz J. Paraoxonase polymorphism Met-Leu54 is associated with modified concentrations of the enzyme. The Journal of Clinical Investigation. 1997 ; 99: 62-66
7. Boemi M, Leviev I, Sirolla C, Pieri C, Marra M, James RW. Serum paraoxonase is reduced in type 1 diabetic patients compared to non-diabetic, first degree relatives; influence on the ability of HDL to protect LDL from oxidation. Atherosclerosis. 2001 ; 155: 229-235 (Pubitemid 32167144)
8. Camps J, Marsillach J, Joven J. The paraoxonases: role in human diseases and methodological difficulties in measurement. Critical Reviews in Clinical Laboratory Sciences. 2009 ; 46: 83-106
9. Davies HG, Richter RJ, Keifer M, Broomfield CA, Sowalla J, Furlong CE. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nature Genetics. 1996 ; 14: 334-336
10. Eckerson HW, Wyte C, La Du BN. The human serum paraoxonase/arylesterase polymorphism. American Journal of Human Genetics. 1983 ; 35: 1126-1138 (Pubitemid 14201166)
11. Ferre N, Tous M, Paul A, Zamora A, Vendrell JJ, Bardaji A, et al. Paraoxonase Gln-Arg (192) and Leu-Met (55) gene polymorphisms and enzyme activity in a population with a low rate of coronary heart disease. Clinical Biochemistry. 2002 ; 35: 197-203 (Pubitemid 34634181)
12. Flekač M, Škrha J, Zidková K, Lacinová Z, Hilgertová J. Paraoxonase 1 gene polymorphisms and enzyme activities in diabetes mellitus. Physiological Research. 2008 ; 57: 717-726
13. Gross ER, Ladisa JF, Weichrauch D, Olson LE, Kress TT, Hettrick DA, et al. Reactive oxygen species modulate coronary wall shear stress and endothelial function during hyperglycemia. American Journal of Physiology. 2003 ; 284: H1552 - H1559
14. Hedrick CC, Thorpe SR, Fu MX, Harper CM, Yoo J, Kim SM, et al. Glycation impairs high-density lipoprotein function. Diabetologia. 2000 ; 43: 312-320 (Pubitemid 30163474)
15. Hofer SE, Bennetts B, Chan AK, Holloway B, Karschimkus C, Jenkins AJ, et al. Association between PON1 polymorphisms, PON activity and diabetes complications. Journal of Diabetes and Its Complications. 2006 ; 20: 322-328 (Pubitemid 44292534)
16. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE. The molecular basis of the human serum paraoxonase activity polymorphism. Nature Genetics. 1993 ; 3: 73-76 (Pubitemid 23063292)
17. Kalousová M, Zima T, Tesař V, Dusilová- Sulková S, Škrha J. Advanced glycoxidation and products in chronic disease-clinical chemistry and genetic background. Mutation Research. 2005 ; 579: 37-46 (Pubitemid 41540131)
18. Karabina SA, Lehner AN, Frank E, Harthasarathy S, Santanam N. Oxidative inactivation of paraoxonase implications in diabetes mellitus and atherosclerosis. Biochimica et Biophysica Acta. 2005 ; 1725: 213-221 (Pubitemid 41253931)
19. Koda Y, Tachida H, Soejima M, Takenaka O, Kimura H. Population differences in DNA sequence variation and linkage disequilibrium at the PON1 gene. Annals of Human Genetics. 2004 ; 68: 110-119 (Pubitemid 38379842)
20. Li B, Sedláček M, Manoharan I, Boopathy R, Duysen EG, Masson P, Lockridge O. Butyrylcholinesterase, paraoxonase and albumin esterase but not carboxylesterase are present in human plasma. Biochemical Pharmacology. 2005 ; 70: 1673-1684 (Pubitemid 41540360)
21. Lotti M Spencer PS Schaumburg H Ludolph AC, ed. Oxford: Oxford University Press ; 2000: 898-925.
22. Mackness B, Durrington PN, Povey A, Thomson S, Dippnall M, Mackness MI, et al. Paraoxonase and susceptibility to organophosporus poisoning in farmers dipping sheep. Pharmacogenetics. 2003 ; 13: 81-88 (Pubitemid 36259587)
23. Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high-density lipoprotein against low-density lipoprotein oxidative modification. FEBS Letters. 1998 ; 423: 57-60 (Pubitemid 28098579)
24. Mackness MI, Harty D, Bhatnagar D, et al. Serum paraoxonase activity in familial hypercholesterolaemia and insulin dependent diabetes mellitus. Atherosclerosis. 1991 ; 86: 193-199
25. Mackness MI, Mackness B, Durrington PN, Conelly PW, Hegele RA. Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Current Opinion in Lipidology. 1996 ; 7: 60-76
26. Marsillach J, Parra S, Ferre N, Coll B, Alonso-Villaverde C, Joven J, Camps J paraoxonase-1 in chronic liver diseases, neurological diseases, and HIV infection The Paraoxonases: Their Role in Disease Development and Xnobiotic Metabolism. Mackness B Mackness M Aviram M Paragh G, ed. Dordrecht: Springer ; 2008: 187-198.
27. Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM, Navab M. Protective effect of high-density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimal oxidized low-density lipoprotein. The Journal of Clinical Investigation. 1995 ; 96: 2882-2891
28. Geneva: WHO ; 1999 :